

VOLLMERS -- 10/578,856
Attorney Docket: 043043-0359294

OK TO ENTER: /L.B./

IN THE SPECIFICATION:

At page 9, lines 1-5, please amend the specification to correct the sequence and terms as follows:

--to Ser-Tyr-Ala-Met-His (CDR1), Val-Ile-Ser-Tyr-Asp-Gly-Ser-Asn-Lys-Tyr-Tyr-Ala-Asp-Ser-Val-Lys-Gly (CDR2) and Asp-Arg-Leu-Ala-Val-Ala-Gly-Lys-Thr-Arg-Pro-Phe-Asp-Tyr (CDR3) of SEQ ID No 3 of the variable region of the light heavy chain (V_H); see also Figure 4 Page 4 of the Listing--

At page 13, lines 8-9, please amend the specification to insert the biological deposit information for SAM-6.10 antibody producing hybridoma as follows:

--For this purpose, the hybridoma cells producing the SAM-6.10 IgM antibodies (DSM ACC2903, deposited April 17, 2008, DSMZ, Inhoffenstr. 7B D-38124 Braunschweig) were cultured in a special serum-free cell culture medium--

At page 21, line 3, please amend the specification to delete "Figure 9" as follows:

--For the stains shown in Figure 9 Figure 5, the macrophages were cultivated for 24 h both with and without FCS supplement. Then, for a further 24 h, either only LDL, or only SAM-6, or LDL and SAM-6 together were respectively added. Subsequently staining with Sudan III was carried out. The left figure column with the Figures 5A, 5C and 5E show cells that were cultivated without supplementation of FCS. The right image column with the Figures 5B, 5D and 5F show cells that were cultivated with supplementation of FCS.--